Despite Advances, Regenerative Medicine Faces Funding Crisis
This article was originally published in Start Up
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. Earlier stage biotechs are trying to turn their platforms into research revenue as they look to non-profit, government, and private funding sources to advance their preclinical therapeutic programs. Whatever the model, worries abound that the financial woes of the next couple of years could blunt hard-earned momentum.
You may also be interested in...
The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.
Former J&J executive Leona Brenner-Gati will become acting deputy commissioner for medical products and tobacco following the departure of Stephen Spielberg.
Former J&J and Sandoz executive Leona Brenner-Gati to become acting deputy commissioner for medical products and tobacco following the departure of Stephen Spielberg.